<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535574</url>
  </required_header>
  <id_info>
    <org_study_id>LRM250850</org_study_id>
    <nct_id>NCT00535574</nct_id>
  </id_info>
  <brief_title>Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia</brief_title>
  <official_title>Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beersheva Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beersheva Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Bexarotene (Targretin) is a synthetic retinoid mainly used for treatment of
      patients suffer from oncological or dermatological diseases. The present study is based on:
      evidence that retinoids are involved in neurodevelopment (&quot;the retinoid dysregulation
      hypothesis&quot;); an assumption that the combined effect of antipsychotic agents and bexarotene
      will have a beneficial effect on schizophrenia patients; and the positive findings from our
      pilot open-label clinical trial (ClinicalTrials.gov Identifier: NCT00141947). However,
      clinical efficacy of bexarotene should be investigated in a placebo-controlled trial.

      Methods: In a 6-week, randomized, double-blind placebo-controlled trial Targretin (75 mg/day)
      or placebo capsules will be added to the stable ongoing antipsychotic treatment of 90
      schizophrenia patients. Participants will be assessed at baseline and after 2, 4 and 6 weeks
      of treatment. A battery of research instruments will be used for assessment of
      psychopathology, side effects, general functioning and quality of life. In addition,
      cholesterol and triglyceride levels, liver and thyroid function tests and a blood cell count
      will be monitored at baseline and during the study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruiting was beginning on November 2008
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS, CDSS, GAF, QLS</measure>
    <time_frame>every two weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Bexarotene (Targretin LGD1069)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexarotene (Targretin LGD1069)</intervention_name>
    <description>75 mg per day for 6 weeks</description>
    <arm_group_label>Bexarotene (Targretin LGD1069)</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bexarotene</intervention_name>
    <description>75 mg/day 6 weeks</description>
    <arm_group_label>Bexarotene (Targretin LGD1069)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-60 years, male or female

          2. DSM-IV criteria for schizophrenia, or schizoaffective disorder.

          3. Ability and willingness to sign informed consent for participation in the study

          4. Stable blood parameters including adequate hematologic function, defined as WBC ≥
             4.300/μL, absolute neutrophil count ≥3.000/μL (&gt; 50%), and platelet count ≥
             180,000/μL; normal coagulation parameters; bilirubin ≤1.5 times the upper limit of
             normal (ULN); AST/ALT ≤ 2.5 × ULN; and serum creatinine ≤1.5 mg/dL.

          5. Only patients who had a normal baseline fasting triglyceride (FTG) level will be
             entered into the study; triglycerides may be normalized before study entry with use of
             an antilipemic agent.

        Exclusion Criteria:

          1. Lipid abnormalities. Fasting triglyceride normal (normalization with an antilipemic
             allowed prior to study entry).

          2. Leucopenia or neutropenia. Hematopoietic: Hemoglobin at least 12.5 g/dL; WBC&lt; 4300/μL;
             Absolute neutrophil count &lt; 3000/μL; Platelet count &lt; 155,000/μL

          3. Evidence of organic brain damage, mental retardation, alcohol or drug abuse

          4. Impairment of renal function

          5. Hepatic dysfunction

          6. A history of pancreatitis

          7. Thyroid axis alterations

          8. Suicide attempt in past year.

          9. Cataracts.

         10. Systemic treatment with more than 15,000 IU of vitamin A daily.

         11. Patients with a known hypersensitivity to bexarotene or other components of the
             product.

         12. Pregnant women or a woman who intends to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Vladimir Lerner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Be'er Sheva Mental Health Center Ben Gurion University of the Negev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Be'er Sheva Mental Health Center</name>
      <address>
        <city>Be'er Sheva,</city>
        <state>Be'er Sheva</state>
        <zip>84170</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abarbanel Mental Health Center</name>
      <address>
        <city>Bat-Yam</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sha'ar Menashe Mental Health Center,</name>
      <address>
        <city>Hadera,</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beersheva Mental Health Center</investigator_affiliation>
    <investigator_full_name>Vladimir Lerner</investigator_full_name>
    <investigator_title>A/Professor, Head of department</investigator_title>
  </responsible_party>
  <keyword>retinoids</keyword>
  <keyword>bexarotene</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>PANSS</keyword>
  <keyword>Positive and negative symptoms of schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

